Results 71 to 80 of about 4,961 (248)
Two Dabigatran Fast Reversals in a 4-month Period – a Case Report
European Journal of Case Reports in Internal Medicine, 2019 Introduction: Idarucizumab is available for immediate reversal of dabigatran-induced anticoagulation in life-threatening bleeding or urgent surgery in patients with non-valvular atrial fibrillation (nvAF).
Vítor Fagundes, Mari Mesquita
doaj +1 more source
Unraveling the Pharmacokinetic Interaction of Ticagrelor and MEDI2452 (Ticagrelor Antidote) by Mathematical Modeling [PDF]
, 2016 The investigational ticagrelor-neutralizing antibody fragment, MEDI2452, is developed to rapidly and specifically reverse the antiplatelet effects of ticagrelor.
Almquist, Joachim +9 more
core +1 more source
The Success of Sinister Right-Handers in Baseball [PDF]
, 2017 Description to be added.Cannot be left ...
Allen, Peter M. +2 more
core +2 more sources
Consensus Guides on Stroke Thrombolysis for Anticoagulated Patients from Japan: Application to Other Populations [PDF]
Journal of Stroke, 2018 Development of direct oral anticoagulants and their antidotes has led to the need to reconsider the eligibility of acute stroke patients who have been taking oral anticoagulants for intravenous thrombolysis.
Kazunori Toyoda +2 more
doaj +1 more source
Direct oral anticoagulants versus warfarin: is new always better than the old? [PDF]
, 2018 About 1.4 British million people are at risk of strokes due to non-valvular atrial fibrillation (AF) necessitating long-term anticoagulation. The vitamin K antagonist, warfarin, has a long half-life and narrow therapeutic range necessitating regular ...
Burn, John, Pirmohamed, Munir
core +1 more source
Measuring Direct Oral Anticoagulant (DOAC) Levels: Applications, Limitations, and Future Directions
International Journal of Laboratory Hematology, EarlyView.ABSTRACT Introduction There are important challenges with the measurement and interpretation of direct oral anticoagulant (DOAC) anticoagulant effect including a lack of therapeutic ranges, inaccuracy of routinely available coagulation assays, lack of established thresholds for clinically significant effect, and uncertainty about how to apply the ...
Siraj Mithoowani +2 more
wiley +1 more source
Frontiers in Aging Neuroscience, 2021 Background: As there is a growing concern about the cerebral embolism events secondary to non-valvular atrial fibrillation (NVAF), novel oral anticoagulant (NOAC) has been more and more widely used as an anticoagulation treatment for the prevention of ...
Dan Xie +7 more
doaj +1 more source
Clinical Studies & Medical Case Reports, 2022 Novel Oral Anticoagulants (NOACs) are widely used in patients with non-valvular atrial fibrillation to prevent Acute Ischemic Stroke (AIS) and other thrombo- embolic phenomena. The management of AIS with Intravenous Thrombolysis Therapy (IVT), also known
T. Ibrahim
semanticscholar +1 more source
European Journal of Clinical Investigation, Volume 55, Issue 9, September 2025.Effective stroke prevention in AF requires a comprehensive holistic approach incorporating appropriate risk stratification, guideline‐adherent anticoagulation and management of underlying cardiovascular conditions and other comorbidities. The ABC pathway, supported by characterisation using the 4S‐AF framework, provides a structured approach to ...
Amir Askarinejad +4 more
wiley +1 more source
Idarucizumab to reverse effects of anticoagulant dabigatran [PDF]
Prescriber, 2016 Idarucizumab (Praxbind) is a new treatment to reverse the effects of the nonvitamin K antagonist oral anticoagulant (NOAC) dabigatran if emergency surgery is needed or to prevent life-threatening or uncontrolled bleeding. This article describes its properties, efficacy and adverse effects.
openaire +2 more sources